Orchid Pharma capex outflow reaches Rs 395.44 crore in half-year

Orchid Pharma Limited recorded a Rs 395.44 crore consolidated cash outflow on property, plant and equipment, including changes in capital work in progress, in the six months ended September 30, 2026, compared with Rs 163.91 crore a year earlier, while consolidated borrowings rose to Rs 543.65 crore.

How much did Orchid Pharma spend on capital expenditure?

Orchid Pharma spent Rs 395.44 crore on property, plant and equipment, including changes in capital work in progress, during the half year ended September 30, 2026. The outflow was higher than Rs 163.91 crore in the six months ended September 30, 2025, an increase of Rs 231.53 crore.

The property, plant and equipment outflow exceeded the group’s Rs 117.78 crore net cash from operating activities in the September 2026 half year. Consolidated investing activities used Rs 314.58 crore overall, compared with Rs 72.48 crore used in the prior-year period, making fixed-asset purchases the largest identified investing outflow in both periods.

The filing does not identify individual projects within the Rs 395.44 crore consolidated asset-purchase line. It reports one operating segment, pharmaceuticals, and the September 30, 2026 balance sheet shows additions in completed property, plant and equipment as well as in capital work in progress.

What changed in Orchid Pharma’s asset base?

Orchid Pharma’s consolidated capital work in progress, or CWIP, rose to Rs 688.12 crore on September 30, 2026 from Rs 340.52 crore on March 31, 2026. The Rs 347.60 crore increase was the largest movement among the main fixed-asset categories disclosed for the six-month interval.

Consolidated property, plant and equipment increased to Rs 722.20 crore from Rs 686.61 crore during the same period. Intangible assets rose to Rs 62.28 crore from Rs 0.60 crore, while intangible assets under development declined to Rs 24.98 crore from Rs 73.08 crore.

Orchid Pharma’s total consolidated non-current assets increased to Rs 1,697.36 crore at September 30, 2026 from Rs 1,329.16 crore at March 31, 2026. Total assets rose to Rs 2,652.35 crore from Rs 2,258.43 crore, while current assets increased to Rs 954.99 crore from Rs 929.26 crore.

How did Orchid Pharma fund its investment outflow?

Orchid Pharma reported Rs 236.34 crore of net cash from financing activities in the half year ended September 30, 2026, compared with Rs 98.08 crore in the comparable 2025 period. Net proceeds from short-term borrowings were Rs 87.90 crore and net proceeds from long-term borrowings were Rs 154.32 crore in the latest half year.

The group generated Rs 117.78 crore of net operating cash in the September 2026 half year, against a Rs 4.70 crore outflow a year earlier. Cash generated from operations was Rs 118.46 crore before net tax payments, with trade payables increasing by Rs 72.20 crore and trade receivables declining by Rs 33.16 crore; inventories absorbed Rs 49.80 crore.

Maturities of bank fixed deposits added Rs 66.80 crore in the investing section, while investment transactions generated Rs 9.01 crore. These inflows partly offset fixed-asset spending, and cash and cash equivalents closed at Rs 46.62 crore on September 30, 2026, up from Rs 7.07 crore at the start of the financial year.

How far did Orchid Pharma’s borrowings rise?

Orchid Pharma reported consolidated borrowings of Rs 543.65 crore at September 30, 2026, comprising Rs 339.06 crore of non-current borrowings and Rs 204.60 crore of current borrowings. At March 31, 2026, consolidated borrowings totalled Rs 301.44 crore, comprising Rs 184.74 crore of non-current and Rs 116.70 crore of current borrowings.

Non-current borrowings increased by Rs 154.32 crore between March 31 and September 30, 2026, while current borrowings increased by Rs 87.90 crore. The movement in each classification matches the respective net proceeds from long-term and short-term borrowings in the consolidated half-year cash-flow statement.

Consolidated finance costs were Rs 5.87 crore in the six months ended September 30, 2026, compared with Rs 4.85 crore a year earlier. Total consolidated liabilities stood at Rs 1,020.07 crore at September 30, up from Rs 694.12 crore at March 31, while total equity increased to Rs 1,632.28 crore from Rs 1,564.31 crore.

What other funding disclosures are relevant to Orchid Pharma?

Orchid Pharma said net proceeds from its qualified institutional placement, or QIP, had been fully utilised by September 30, 2026. The utilisation statement records Rs 135 crore for investment in subsidiary Orchid Bio-Pharma Limited’s Jammu manufacturing facility, Rs 195.46 crore for repayment or prepayment of borrowings, Rs 36 lakh for a new block at the Alathur active pharmaceutical ingredient, or API, facility, and Rs 63.72 crore for general corporate purposes.

The QIP utilisation table records total proceeds of Rs 394.54 crore and total utilisation of Rs 394.54 crore as of September 30, 2026. Orchid Pharma also said the allocation among the QIP objects had been revised through a shareholder resolution dated September 20, 2025.

The board approved Orchid Pharma’s unaudited standalone and consolidated results on November 14, 2026. Singhi & Co.’s review reports state that nothing came to the auditor’s attention indicating that the results were materially misstated under the applicable financial-reporting requirements.

Conclusion

Orchid Pharma’s September 2026 half-year accounts show substantially higher investment in fixed assets and projects under development. The Rs 395.44 crore capital-expenditure cash outflow was supported by Rs 117.78 crore of operating cash generation, Rs 236.34 crore of net financing inflow and other investing inflows, while total borrowings rose by Rs 242.21 crore from March 31, 2026.

The next results will show whether the Rs 688.12 crore CWIP balance moves into completed property, plant and equipment, and whether the Jammu manufacturing facility and Alathur API-facility block progress under the disclosed plans. With QIP proceeds fully utilised by September 30, 2026, subsequent cash-flow statements will also show changes in operating cash generation and borrowing flows.